

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 041 151 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

04.10.2000 Bulletin 2000/40

(51) Int. Cl.<sup>7</sup>: **C12N 15/53, C12N 9/02,****C12N 15/63, C12N 1/21,****C12Q 1/26**(21) Application number: **98961523.2**(22) Date of filing: **24.12.1998**

(86) International application number:

**PCT/JP98/05864**

(87) International publication number:

**WO 99/33997 (08.07.1999 Gazette 1999/27)**(84) Designated Contracting States:  
**DE GB NL**(30) Priority: **26.12.1997 JP 36102297**(71) Applicant: **KIKKOMAN CORPORATION**  
**Noda-shi, Chiba 278-8601 (JP)**

(72) Inventors:

- **HATTORI, Noriaki**  
**Kikkoman Corporation**  
**Noda-shi, Chiba 278-8601 (JP)**

- **MURAKAMI, Seiji,**  
**Kikkoman Corporation**  
**Noda-shi, Chiba 278-8601 (JP)**

(74) Representative:

**Brasnett, Adrian Hugh et al**  
**Mewburn Ellis**  
**York House**  
**23 Kingsway**  
**London WC2B 6HP (GB)**

(54) **LUCIFERASE AND METHOD FOR ASSAYING INTRACELLULAR ATP BY USING THE SAME**

(57) The present invention relates to luciferase having resistance to a surfactant and a method for measuring intracellular ATP which is characterized in that the luciferase having resistance to a surfactant is used in this method comprising the steps of: a first step wherein ATP is extracted from cells in a sample; a second step wherein light emission is produced by adding a luminescence reagent containing luciferase to the extracted ATP solution; and a third step wherein the light emission is measured.

EP 1 041 151 A1

BEST AVAILABLE COPY

## EP 1 041 151 A1

## Description

## Technical Field

- 5 [0001] The present invention relates to novel luciferase having resistance to a surfactant and a method for measuring intracellular ATP using the same.

## Background Art

- 10 [0002] Intracellular ATP is routinely measured for determining the presence of cells in a sample or the number of cells in the fields of food sanitation, biology, clinical examinations, medical science, ultrapure water, and environmental science. A general method for measuring intracellular ATP comprises the steps of adding an ATP extraction reagent containing a surfactant as an effective component to a sample containing cells, extracting intracellular ATP, adding a luminescence reagent containing luciferase into the sample, and then measuring the total amount of light emitted.

- 15 [0003] Luciferase is an enzyme that catalyzes luminescence reaction of luciferin, which is a substrate, in the presence of ATP and magnesium ion. Luciferase used in a method for measuring intracellular ATP includes those derived from firefly species, such as GENJI firefly (*Luciola cruciata*), HEIKE firefly (*Luciola lateralis*), North American firefly and Russian firefly, etc.

- 20 [0004] Intracellular ATP can be extracted by adding an ATP extraction reagent to a sample containing cells and then stirring the sample.

- To make full use of the capabilities of the extraction reagent, preferably the reaction agent is added so that the concentration of a surfactant becomes 0.05% or more of the mixture of the sample and the extraction reagent. However, a condition where the concentration of the surfactant is 0.05% or more, this inhibits significantly the enzyme reaction in the process of measuring ATP concentration by bioluminescence. Thus the sensitivity and accuracy of measurement are largely impaired. This is because a surfactant at such a high concentration lowers luciferase activity.  
25 For example, North American firefly luciferase activity decreases to about 20% in the presence of 0.1% benzalkonium chloride (See Table 1).

- [0005] On the other hand, inhibition of the bioluminescent reaction can be reduced with a lower concentration of surfactant. However, in this case the extraction efficiency for ATP would be insufficient.

- 30 [0006] A method wherein cyclodextrin or its derivative is used is a known method for suppressing the inhibition of luminescence reaction by a surfactant (Japanese Patent Application Laid-Open No. 6-504200).

- Among methods for measuring intracellular ATP wherein intracellular ATP is extracted by allowing a sample to contact with a surfactant and subsequently ATP is measured by luciferin-luciferase bioluminescent reaction method, a method for measuring intracellular ATP characterized by the application of the bioluminescent reaction method after allowing a sample, from which ATP is extracted, to contact with cyclodextrin (Japanese Patent Application Laid-Open Publication No. 7-203995) is also known.

- [0007] There has been no attempt so far to suppress the inhibition of bioluminescent reaction due to a surfactant focusing on luciferase.

- 40 [0008] The purpose of the invention is to provide a novel luciferase having anti-surfactant resistance, whose activity is not impaired by the presence of a surfactant at a high concentration. The other purpose of the invention is to provide a method, comprising the steps of extracting intracellular ATP using a surfactant and measuring intracellular ATP by bioluminescent reaction using a luciferase, which can lower the inhibition of bioluminescent reaction due to a surfactant without a decrease in efficiency in extracting intracellular ATP.

- 45 [0009] In the context of this Specification, the term "suppress" is used to describe significant reduction of the inhibition of the luminescence reaction by a surfactant and the complete elimination of this inhibition.

## Disclosure of the Invention

- [0010] The present invention relates to a luciferase having anti-surfactant resistance.

- 50 [0011] The luciferase having resistance to a surfactant includes a luciferase, wherein an amino acid at the 490-position, or an amino acid corresponding to the amino acid at 490-position of GENJI firefly or HEIKE firefly is substituted by an amino acid other than glutamic acid, e.g., lysine, in the amino acid sequence of a wild-type firefly luciferase.

- [0012] Further, the luciferase having resistance to a surfactant includes a polypeptide consisting of (a) or (b):

- 55 (a) A polypeptide consisting of the amino acid sequence shown in SEQ ID NO:4,  
(b) A polypeptide comprising additions, deletions, or substitutions of one or more of amino acids in the polypeptide of (a), and having luciferase activity resistant to a surfactant, or

## EP 1 041 151 A1

a polypeptide consisting of (a) or (b):

- (a) A protein consisting of an amino acid sequence shown in SEQ ID NO:6,  
(b) A protein comprising additions, deletions, or substitutions of one or more of amino acids in the polypeptide of  
5 (a), and having luciferase activity resistant to a surfactant.

[0013] Further, the present invention relates to a luciferase gene encoding the luciferase having resistance to a surfactant.

10 [0014] Furthermore, the present invention relates to a recombinant vector containing the luciferase gene encoding the luciferase having resistance to a surfactant.

[0015] The present invention also relates to a transformant containing the recombinant vector.

[0016] In addition, the present invention relates to a method for producing the luciferase, comprising the steps of culturing the recombinant in a medium, and collecting luciferase with resistance to a surfactant from the culture product.

15 [0017] Moreover the present invention relates to a method for measuring intracellular ATP, comprising the steps of a first step wherein ATP is extracted in the presence of a surfactant from cells in a sample; a second step wherein a luminescence reagent containing luciferase is added to the extracted ATP solution so as to cause light emission; and a third step wherein the light emission is measured, and characterized in that luciferase having resistance to a surfactant is used.

20 [0018] This specification encompasses the description and/or drawings given in Japanese Patent Application No. H09-361022.

#### Brief Description of Drawings

[0019]

25 Figure 1 shows a production processes for a mutant luciferase HIK.

Figure 2 shows change with time of light emission from natural type luciferase.

Figure 3 shows a comparative resistance against benzalkonium chloride of mutant luciferase.

30 Figure 4 shows a comparative resistance against benzetonium chloride of mutant luciferase

#### Detailed Description of the Invention

[0020] The present invention will now be described in detail.

35 [Luciferase having resistance to surfactant]

[0021] Luciferase having resistance to a surfactant according to the present invention is as described below. The term "having resistance to a surfactant" corresponds to any one of the following features.

40 (1) When compared to known luciferase, the luciferase of the present invention leads to an increased initial amount of light emitted in the presence of a surfactant. Here the term "compare" means, for example, where the luciferase of the present invention is produced by introducing mutation into an amino acid sequence of known luciferase, to compare light emission from luciferase before and after the introduction of a mutation.

45 (2) When compared to known luciferase, the luciferase of the present invention shows a gentle decrease in its activity in the presence of a surfactant.

(3) The luciferase of the present invention has the remaining activity of more than 85% in the presence of 0.4% surfactant.

[0022] Hereinafter "luciferase having resistance to a surfactant" is referred to as "surfactant - resistant luciferase."

50 [0023] The term "activity" means the catalytic activity of bioluminescent reaction. Further any surfactant can be used in the present invention so far as it can be used in the measurement system for intracellular ATP. These surfactants include an anionic surfactant, cationic surfactant, ampholytic surfactant, non-ionic surfactant. A specific reagent is benzalkonium chloride or benzetonium chloride containing quaternary ammonium salt as a major component.

55 [0024] The luciferase of the present invention can be prepared from luminescence organs of luminescent organisms. The luminescent organisms include luminescent insects and luminescent bacteria. The luminescent insects include those belonging to the order Coleoptera, such as those belonging to the family firefly and the family Pyrophorus. Specific examples include GENJI firefly, HEIKE firefly, North American firefly, Russian firefly, Pyrophorus plagiophthalmus, Arachnocampa luminosa, and Rail worm. Further the luciferase of the present invention is obtained by cloning

## EP 1 041 151 A1

a luciferase gene from the luminescent organism and allowing the gene to express using an appropriate vector - host system.

[0025] Moreover, the luciferase of the present invention can be obtained by introducing mutation such as additions, deletions, and substitutions into an amino acid sequence of well-known luciferase. Well-known genetic engineering techniques can be used to introduce mutation into an amino acid sequence. In this case firstly, a mutation such as an addition, deletion, or substitution is introduced into a nucleotide sequence of a luciferase gene derived from the above-mentioned luminescent organism or a well-known luciferase gene by genetic engineering techniques so as to generate a mutant luciferase gene. Subsequently, the mutant gene is incorporated into an appropriate host-vector system, thereby generating a recombinant microorganism. Then the recombinant microorganisms producing the luciferase of the present invention are selected by screening. The selected recombinant microorganisms are cultured in a medium. Finally, the luciferase can be collected from the culture product.

[0026] Hereinafter surfactant-resistant luciferase obtained by introduction of a mutation into an amino acid sequence is referred to as "mutant luciferase."

[0027] The mutant luciferase is for example, luciferase wherein an amino acid corresponding to an amino acid at the 490-position of the GENJI firefly luciferase or the HEIKE firefly luciferase, is substituted by an amino acid other than glutamic acid in an amino acid sequence of a wild-type firefly luciferase. The amino acid other than glutamic acid is a basic amino acid. Specific examples include lysine, arginine, and histidine. The term "an amino acid corresponding to the amino acid at the 490-position of the GENJI or the HEIKE firefly luciferase" means an amino acid corresponding to the amino acid at the 490-position of the GENJI or HEIKE firefly luciferase when the determined amino acid sequence of luciferase is compared to an amino acid sequence of the GENJI or HEIKE firefly luciferase.

[0028] Moreover, in the GENJI or HEIKE firefly luciferase, the amino acid at the 490-position is glutamic acid. Further, in North American firefly luciferase, "an amino acid corresponding to the amino acid at the 490-position of the GENJI or the HEIKE firefly luciferase" corresponds to the glutamic acid at the 487-position.

[0029] More specifically, the mutant luciferase is a polypeptide comprising an amino acid sequence shown in SEQ ID NO:1 or 2, or said amino acid sequence wherein one or more amino acids are added, deleted or substituted.

[Method for producing mutant luciferase by genetic engineering techniques]

[0030] A method for generating mutant luciferase by genetic engineering techniques will now be described as follows.

[0031] The mutant luciferase is produced by introducing mutation such as additions, deletions, and substitutions into a nucleotide sequence of known luciferase and allowing an appropriate vector-host system to express the gene.

[0032] The known luciferase genes includes, but are not limited to, a firefly luciferase gene, more specifically a wild-type HEIKE firefly luciferase gene (Japanese Patent Application Laid-Open No. 2-17 1189) and a thermostable HEIKE firefly luciferase gene (Japanese Patent Application Laid-Open No. 5-244942).

i) A method for introducing mutation into a luciferase gene is, for example a method wherein the gene and a mutagen are allowed to contact with each other. Specific examples of the mutagen include hydroxylamine, nitrous acid, sulfurous acid, and 5-bromouracil. Further, ultra violet irradiation, cassette mutagenesis, and site-directed mutagenesis using PCR can also be used. Furthermore, a mutant luciferase gene having a mutation at a desired position can be generated by annealing chemically synthesized DNA.

ii) Next, the mutant luciferase gene is inserted into a vector DNA having such as a promoter sequence, a marker gene, and a replication origin, etc, thereby producing a recombinant plasmid. Any vector DNA can be used so far as it can be replicated in a host cell. Examples of the vector DNA include plasmid DNA and bacteriophage DNA. When the host cell is *Escherichia coli*, examples of the vector DNA include plasmid pUC119 (Takara Shuzo Co., Ltd.), pBluescript SK+ (Stratagene), pMAL-C2 (NEW England Labs), pGEX-5X-1 (Pharmacia), pXa1 (Boehringer), and pMA56 (G. Ammerer, Meth. Enzymol., 101, 192, 1983).

iii) Subsequently, an appropriate host cell is transformed or transduced with the above recombinant plasmid, and screening is performed for recombinant microorganisms having the ability to produce the mutant luciferase.

[0033] Any host cells including eucaryotic and prokaryotic cells can be used. The eucaryotic cells include animal, plant, insect, yeast cells. The prokaryotic cells include *Escherichia coli*, *Bacillus subtilis*, and *Actinomyces*. The animal cells include CHO, COS, HeLa cells and cells of myeloma cell lines. The prokaryotic cells include microorganisms belong to the genus *Escherichia*, such as *Escherichia coli* JM101 (ATCC 33876), JM109 (produced by Takara Shuzo Co., Ltd.), XL1-Blue (produced by Stratagene), and HB101 (ATCC33694).

[0034] Transformation in the present invention can be performed by for example, D.M. Morrison's method (Meth. Enzymol., 68, 326-331, 1979); Transduction can be conducted by for example, B.Hohn's method (Met. Enzymol., 68, 299-309, 1979). Methods for purification of recombinant DNA from recombinant microorganisms include P.Guerry's

## EP 1 041 151 A1

method (J.Bacteriology, 116, 1064-1066, 1973), and D.B.Clewell's method (J.Bacteriology, 110, 667-676, 1972).

The nucleotide sequence of a gene inserted into the recombinant DNA can be determined by, for example Maxam-Gilbert method (Proc. Natl. Acad. Sci. USA, 74, 560-564, 1977), and Dideoxy method (Proc. Natl. Acad. Sci. USA, 74, 5463-5467, 1977).

- iv) The mutant luciferase of the present invention can be produced by culturing the recombinant microorganisms obtained in the manner described above in media.

[0035] When the host cell is *Escherichia coli*, recombinant *E.coli* may be cultured by solid culture methods, preferably liquid culture methods.

A culture medium of the present invention contains one or more nitrogen sources, such as yeast extract, tryptone, peptone, meat extract, corn steep liquor or exudate of soy bean or wheat bran, to which one or more of inorganic salts, such as sodium chloride, potassium phosphate, dipotassium phosphate, magnesium sulfate, magnesium chloride, ferric chloride, ferric sulfate or manganese sulfate are added. If necessary sugar and vitamins are added to this medium. Further the initial pH of the medium is preferably adjusted within pH 7 to 9. Moreover the culture is performed at a temperature within 30°C to 42°C, preferably at around 37°C for 3 to 24 hours, preferably for 5 to 8 hours. Preferable culture methods include aeration-agitation submerged culture, shaking culture, and static culture.

[0036] To recover mutant luciferase from the culture product after the completion of culturing recombinant *E.coli*, standard means for collecting enzymes can be employed. That is, the culture product is centrifuged to obtain cells.

Then the cells are disrupted by treatment with lytic enzymes, such as lysozyme, ultrasonication, or milling. Fused protein is discharged out of the cell. Subsequently insoluble substances are removed by filtration or centrifugation, so that a crude enzyme solution containing mutant luciferase can be obtained.

[0037] In the present invention the above crude enzyme solution can be used as authentic protein matter, or alternatively it can further be purified to higher purity by standard protein purification techniques. These techniques including sulfate salting out, organic solvent precipitation, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, adsorption chromatography, affinity chromatography, and electrophoresis can be used solely or in combination.

[0038] The use of surfactant-resistant luciferase of the present invention allows the addition of a surfactant at a high concentration in the extraction process for intracellular ATP.

[Detection of intracellular ATP of the present invention]

[0039] Detection of intracellular ATP of the present invention will be described as follows.

- i) First, ATP extraction reagent containing surfactant as an effective component is added to a sample containing cells so as to extract intracellular ATP out of the cells. The term "cells" refers to the cells derived from animal, plant, microorganism (e.g., yeasts, mold, fungi, bacteria, actinomyces, unicellular algae, viruses, and protozoa).

Any sample can be used so far as it contains the above cells. These samples include, but are not limited to, foods and drinks, pharmaceuticals, cosmetics, seawater, river water, industrial water, sewage, soil, urine, feces, blood, sputum, pus, and culture product of the above cells. A sample solution can also be prepared by suspending these samples in an appropriate solvent, such as distilled water, physiological saline, phosphoric acid buffer, Tris buffer, or sodium acetate buffer. When a fluid specimen contains solids, the fluid specimen is suspended in an appropriate solvent or homogenized using a mixer so that it can be handled in the same manner as that in liquid form.

A sample of a filter membrane can also be prepared by filtering the above sample in liquid form through a hydrophilic or hydrophobic filter membrane. The hydrophilic or hydrophobic filter membrane by which cells are captured can be used as a sample. In such a case, a film- or sheet-type hydrophilic filter membrane made of hydrophilic polytetrafluoroethylene, hydrophilic polyvinylidene fluoride, hydrophilic polyamide, acetylcellulose, and nitrocellulose, etc., can be used. Hydrophobic filter membranes made of PVDF (polyvinylidene fluoride), PTFE (polytetrafluoroethylene), and PE (polyethylene) etc., can be used.

Surfactants include anionic surfactants, cationic surfactants, ampholytic surfactants, and non-ionic surfactants. Anionic surfactants include sodium dodecyl sulfate (SDS), lauryl potassium sulfate, sodium monolauryl phosphate, and sodium alkylbenzenesulfonic acid. Cationic surfactants include benzalkonium chloride (BAC), benzetrium chloride (BZC), cetylpyridinium chloride, cetyltrimethylammonium bromide, and myristyldimethylbenzylammonium chloride. Ampholytic surfactants include Twittergent Detergent 3-08, 3-10, 3-12, 3-14, 3-16, and Tego. Finally non-ionic surfactants include Tween 20, 60, and 80, Span 60 and 80, Triton X-45 and X-100, polyoxyethylene ether, and polyoxyethylene lauryl ether.

Any concentration of a surfactant can be employed so far as it allows full expression of the ability to extract ATP.

## EP 1 041 151 A1

Preferable concentration of a surfactant is 0.05% or more of the mixture of a sample and ATP extraction reagent.

A sample and ATP extraction reagent are contacted with from each other at room temperature or with heating.

ii) After ATP extraction, bioluminescent reagent is added to the sample containing surfactant-resistant luciferase so as to cause emission. Then the light emission is measured.

When surfactant-resistant luciferase is derived from a firefly, the bioluminescent reagents are those containing e.g., the following components (a) to (c).

- (a) surfactant-resistant luciferase
- (b) luciferin
- (c) magnesium ions or other metal ions

Further in addition to the above components, substances involving pH preparation or improved shelf life may be added. Such substances include EDTA 2Na, dithiothreitol, ammonium sulfate, sucrose, 2-mercaptoethanol, HEPES, Tricine, and Tris.

iii) The amount of light emitted by the addition of a bioluminescent reagent can be measured by a luminometer such as a lumitester K-100 produced by Kikkoman Corporation, a luminescence reader BLR-201 produced by Aloka Co., Ltd. (an improved type), or a Lumat LB9501 produced by Berthold. When a filter membrane by which cells are captured is used as a sample, the cells can be counted using a bioluminescent image analysis system device to photograph spots on the filter membrane. Such a device is ARGUS-50/CL (with taper fiber: produced by Hamamatsu Photonics K.K.).

[0040] The present invention will now be described in detail by the use of examples.

[0041] However the technical field of the present invention is not limited by these examples.

#### Example 1 Surfactant resistance of natural type luciferase derived from various fire fly species.

(Method of preparing wild type luciferase derived from various firefly species)

[0042] Luciferase derived from GENJI and HEIKE fireflies was prepared according to the following methods. 1 mM ethylene diamine-4-acetate-2-sodium and 2mM phenylmethylsulfonylfluoride were added to 25mM Tris (hydroxy) aminomethanhydrochloric acid buffer. Further ammonium sulfate was added to this solution so as to achieve 10% saturation. Tail portions of the various firefly species were added to this mixture at pH 7.8, and then disrupted using Hiskotoron (produced by Nichionrikakikaiseisakusho). The resulting solution was centrifuged at 12,000 r.p.m. for 20 minutes to obtain supernatants as starting materials for purification. The purification was conducted by the process comprising salting out of ammonium sulfate, Ultrogel Ac A34 (produced by LKB) column, and hydroxy-apatite HPLC (produced by TOSHOH, TSK gel HA-1000) column. Finally an electrophoretically homogenous sample was obtained. In addition the luciferase derived from North American firefly is a commercial product (Sigma, L-9506).

(Method of determining luciferase activity)

[0043] A luciferase sample was properly diluted using enzyme-diluted solution (1mM EDTA, 1mM 2-mercaptoethanol, 1% BSA, 50mM HEPES, (pH7.5)). To 100  $\mu$ l of this solution, 100  $\mu$ l of substrate solution (1.4mM luciferin, 40mM ATP, 300mM MgSO<sub>4</sub> · 7H<sub>2</sub>O, 50mM HEPES, (pH 7.5)) was added.

The light emission was measured using BLE-201 Luminescence reader (produced by Aloka Co., Ltd.) under the following conditions.

Measuring range: x100  
Numerical value displayed: x1000  
Measuring temperature: 30°C  
Measuring time: 20 seconds

[0044] 1 MLU (mega light unit) /ml is a value for activity when the measured value under these conditions was 1 Kcount.

## EP 1 041 151 A1

## (Method of determining surfactant-resistance)

[0045] Enzyme samples were obtained by preparing luciferase samples derived from various firefly species using enzyme-diluted solution (1mM EDTA, 1mM 2-mercaptoethanol, 5% glycerol, 50mM HEPES, (pH7.5)) to achieve 0.5

5 MLU/ml concentration.

[0046] 50 $\mu$ l of 0.4% benzalkonium chloride (25mM Tricine at pH 7.75) and then 50  $\mu$ l of the enzyme sample were added to 100  $\mu$ l of substrate solution (4mM ATP, 0.4mM luciferin, 10mM magnesium sulfate, 50mM HEPES (pH 7.5)). After the solution was stirred for 5 seconds, the light emission was measured every second using Berthold Lumal LB-9501 for 1 minute.

10 [0047] Figure 2 shows the results. Along the vertical axis in this figure, the relative ratio of the light emission was plotted with the initial amount of light emitted considered to be 100% upon use of 25mM Tricine (pH 7.75) instead of 0.4% benzalkonium chloride.

[0048] As shown in these results, North American firefly luciferase was low in the initial light emission and the light emission decayed rapidly. This was caused by the low surfactant-resistance of the North American firefly luciferase.

15 This can lead to low sensitivity and accuracy in measuring such values. On the other hand GENJI firefly luciferase showed an initial light emission higher than that of North American firefly luciferase. That is, GENJI firefly luciferase was shown to have a surfactant resistance superior to that of North American firefly luciferase. Furthermore, HEIKE firefly luciferase showed an initial light emission higher than that of GENJI firefly luciferase and the emission decayed slowly. Therefore, HEIKE firefly luciferase has good surfactant resistance, superior to that of GENJI firefly luciferase. These

20 results suggest that the degree of surfactant resistance of luciferase varies according to the firefly species.

## Example 2 Preparation of mutant luciferase HLK and HIK

[0049] Two types of mutant luciferase (named "HLK" and "HIK") were prepared according to the following methods.

## 25 (Production of a gene encoding mutant luciferase HLK)

[0050] A mutant luciferase gene was produced by site-directed mutagenesis using PCR. A plasmid pHLI7-217Leu described in Japanese Patent Application Laid-Open No. 5-244942 was used as a template for PCR reaction. The

30 pHLI7-217Leu was a recombinant plasmid prepared by inserting a thermostable HEIKE firefly luciferase gene, in which an amino acid corresponding to Ala at the 217-position was substituted for a Leu-encoding gene, into a plasmid pUC119. In addition, E. coli JM101, to which the recombinant plasmid pHLI7-217Leu had been introduced, has been named E.coli JM101 (pHLI7-217Leu) and was deposited on April 22, 1992 as FERM BP-3840 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-

35 shi, Ibaraki-ken, Japan).

[0051] The primer for PCR reaction was an oligonucleotide having a nucleotide sequence shown in SEQ ID No: 1 or 2. The DNA polymerase was a KOD dash polymerase (produced by TOYOBO). A PCR reaction cycle (94°C for 30 seconds, 50°C for 2 seconds, and 74°C for 3 minutes) was repeated for 30 times according to the examples attached to KOD dash polymerase. The PCR product was ligated into a circular recombinant plasmid pHLILK using standard techniques.

40 [0052] Sequencing of a mutant luciferase gene contained in the pHLILK was performed.

[0053] Reaction was conducted using a Diprimer Taq Sequencing Kit (produced by Applied Biosystems). Then the electrophoretic analysis was performed using ABI 373A DNA sequencer (produced by Applied Biosystems). The entire nucleotide sequence of the obtained mutant luciferase gene is shown in SEQ ID NO: 3, and the amino acid sequence

45 of a polypeptide encoded by this gene is shown in SEQ ID NO: 4. In the mutant luciferase gene, the genetic portion corresponding to alanine at the 217-position of wild-type HEIKE firefly luciferase was substituted by a gene encoding leucine, the genetic portion corresponding to glutamic acid at the 490-position of the same was substituted by a gene encoding lysine. The pHLILK-introduced E.coli JM 109 strain was named E.coli JM109 (pHLILK) (see Figure 1). E. coli JM109 (pHLILK) was deposited as FERM BP-6147 on October 16, 1997) with the National Institute of Bioscience and

50 Human-Technology, Agency of Industrial Science and Technology, Japan.

[0054] The polypeptide shown in SEQ ID NO.4 was named the mutant luciferase HLK.

## (Preparation of gene encoding mutant luciferase HIK)

55 [0055] A mutant luciferase gene was prepared using the plasmid pHLI7-217Ile described in Japanese Patent Application Laid-Open No. 5-244942. The plasmid pHLI7-217Ile was a recombinant plasmid prepared by inserting a thermostable HEIKE firefly luciferase gene, in which an amino acid corresponding to Ala at the 217-position was substituted for a Ile-encoding gene, into a plasmid pUC119. The transformant strain obtained using this plasmid was deposited on

## EP 1 041 151 A1

April 22, 1992 as FERM BP-3841 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan.

[0056] About a 560bp fragment obtained by cutting the pHLfLK with EcoRV and NarI was obtained by agarose gel electrophoresis. Then the fragment was inserted into the pHLf7-217Ile treated with the same restriction enzymes.

[0057] The resulting recombinant plasmid has been named pHLfIK and the plasmid-introduced E.coli JM109 strain has been named E.coli JM109 (pHLfIK).

E.coli JM109 (pHLfIK) was deposited on October 16, 1997 as FERM BP-6146 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan.

[0058] The entire nucleotide sequence of the mutant luciferase gene contained in the pHLfIK is shown in SEQ ID NO: 5, and the amino acid sequence of a polypeptide encoded by this gene is shown in SEQ ID NO: 6. In the mutant luciferase gene, the genetic portion corresponding to alanine at the 217-position of wild-type HEIKE firefly luciferase was substituted by a gene encoding isoleucine, the genetic portion corresponding to glutamic acid at the 490-position of the same was substituted by a gene encoding lysine (see Fig. 1).

[0059] A polypeptide shown in SEQ ID NO 6 was named the mutant HIK firefly.

### Example 3 Preparation of mutant luciferase HLK and HIK

[0060] E.coli JM109 (pHLfLK) and E.coli JM109 (pHLfIK) were inoculated on LB media (1% Bacto-trypton (W/V), 0.5% yeast extract (W/V), 0.5% NaCl (W/V), ampicillin (50 µg/ml), 1.4% agar (W/V)), each containing ampicillin, and cultured at 37°C for 18 hours. The resulting culture fluid was centrifuged at 8000 r.p.m. for 10 minutes. The precipitated cells were suspended in 0.1M potassium phosphate buffer at pH 7.8 (0.1M ammonium sulfate, 1mM EDTA) were disrupted by ultrasonication.

[0061] Next, crude enzyme solution was obtained by centrifugation at 12000 r.p.m. for 10 minutes. The obtained enzyme solution was purified using the above purification techniques such that it becomes an electrophoretically homogenous sample.

### Example 4 Surfactant resistance of mutant luciferase HLK and HIK

(Changes in emission with time)

[0062] To compare surfactant resistance of mutant luciferase with that of known luciferase, changes in emission with time were measured according to the aforementioned methods of measuring surfactant resistance. Figure 3 shows the results obtained by the use of 0.4% benzalkonium chloride (25mM Tricine (pH 7.75)). Figure 4 shows the results obtained by the use of 0.8% benzethonium chloride (25mM Tricine (pH 7.75)).

[0063] "HEIKE I mutant" in this figure is thermostable HEIKE firefly luciferase (described in Japanese Patent Application Laid-Open No. 5-244942) wherein Ala at the 217-position of wild-type HEIKE firefly luciferase is substituted for Ile. "HEIKE L mutant" is thermostable HEIKE firefly luciferase (Japanese Patent Application Laid-Open No. 5-244942) wherein Ala at the 217 position of wild-type HEIKE luciferase is substituted by Leu. "HIK" is a mutant wherein Glu at the 490-position of HEIKE I mutant is substituted by Lys, that is, the mutant luciferase HIK prepared in Example 3. "HLK" is a mutant wherein Glu at the 490-position of HEIKE L mutant is substituted by Lys, that is, the mutant luciferase HLK prepared in Example 3.

[0064] As can be seen in Fig. 3 which shows the results for benzalkonium chloride, the emission of HIK decayed more slowly than that of the HEIKE I mutant. Comparison of HLK and HEIKE L mutant reveals that HLK had initial light emission improved by about 20%, and slower decay in the light emission.

Therefore, the substitution of an amino acid at the 490-position resulted in improved surfactant-resistance of a luciferase.

[0065] As shown in Fig. 4 which shows the results obtained by the use of benzethonium chloride, HIK showed decay in emission more slowly than that of HEIKE I mutant. Further HLK showed slower decay in light emission than that of HEIKE L mutant. Therefore, the substitution of an amino acid at the 490-position resulted in improved surfactant resistance

(Comparison of emission rate)

[0066] The influence of the enzyme solution, substrate solution and benzalkonium chloride used when measuring change with time, on the measurement values taken under actual emission measurement conditions, was examined. Table 1 shows the light emission measured using Berthold Lumat LB-9501 under measuring conditions (5 seconds of waiting time, 3 seconds of measuring time).

In addition, the emission rate (remaining activity) was calculated by dividing the light emission measured in the pres-



## EP 1 041 151 A1

ence of 0.4% benzalkonium chloride by a control value. Here the control value was the light emission upon use of 25mM Tricine at pH 7.75 instead of 0.4% benzalkonium chloride.

Table 1

Luciferase type	Light emission (RLU)		Emission rate (%)
	Without extraction reagent	With extraction reagent	
North American firefly	452563	97790	21.6
GENJI firefly	409406	167805	41.0
HEIKE firefly	425792	324724	76.3
HEIKE I mutant	422269	341039	80.8
HEIKE L mutant	423728	343634	81.1
HIK	386429	345159	89.3
HLK	390289	396764	101.7

[0067] North American firefly luciferase showed an emission rate as low as 21.6%, suggesting a large decrease in sensitivity. On the other hand, the emission rates for GENJI and HEIKE firefly luciferase were 41.0% and 76.3%, respectively, suggesting that the sensitivity of these firefly luciferases were less affected than that of North American firefly luciferase.

[0068] The emission rate for mutant luciferase HIK and HLK were 89.3% and 101.7%, respectively. These rates were far greater than those of wild-type HEIKE firefly luciferase and thermostable HEIKE firefly luciferase. Particularly the emission rate of HLK was almost 100%. That is, HLK can yield the same light emission regardless of the presence or absence of a surfactant. Therefore, the sensitivity of HLK is totally unaffected by the use of a surfactant, allowing measurement with high accuracy.

(Comparison of IC<sub>50</sub>)

[0069] Benzalkonium chloride and various luciferases were contacted with each other for 10 minutes. Then the benzalkonium chloride concentration (IC<sub>50</sub>), at which activity is inactivated by 50% was determined. Equal amounts of luciferase solution prepared at this concentration and 0.01 to 0.1% benzalkonium chloride were mixed, and then allowed to stand for 10 minutes at room temperature. Subsequently, 100  $\mu$ l of substrate solution was added to the mixture. Immediately after addition, the light emission was measured using Berthold Lumat LB-9501. IC<sub>50</sub>s obtained were as shown in Table 2.

Table 2

IC <sub>50</sub> for various luciferase	
Luciferase type	IC <sub>50</sub> (%)
North American firefly	0.014
GENJI firefly luciferase	0.016
HEIKE firefly luciferase	0.026
HEIKE I mutant	0.028
HEIKE L mutant	0.028
HIK	0.032
HLK	0.035

[0070] North American firefly luciferase showed the lowest IC<sub>50</sub> among the three types of wild-type luciferase. That is, North American firefly luciferase was shown to have the lowest resistance to a surfactant. HEIKE firefly luciferase

## EP 1 041 151 A1

showed the highest  $IC_{50}$  among the wild-type luciferase. HLK and HIK showed  $IC_{50}$  higher than those of wild-type HEIKE firefly luciferase and thermostable HEIKE firefly luciferase, suggesting that the resistance was improved by the substitution of an amino acid at the 490-position.

[0071] Especially HLK showed  $IC_{50}$  higher than that of HIK, indicating that HLK possesses the best surfactant-resistance.

#### Example 5 Method for measuring intracellular ATP

[0072] Next, a method for measuring intracellular ATP using the surfactant-resistant luciferase of the present invention will be described.

[0073] A standard technique used herein was TCA extraction method wherein intracellular ATP is extracted using trichloroacetic acid (TCA) and the amount of ATP extracted is measured using luciferin-luciferase luminescence reaction. TCA extraction method is excellent in extraction efficiency. Further in TCA extraction method no inhibition of luminescence reaction is caused by TCA because emission is measured after the sample containing TCA is diluted 1:100. Because of this dilution, however, TCA extraction method is complicated and can cause a decrease in the measuring sensitivity.

#### 1. Materials

##### [0074]

##### (1) Surfactant

Benzalkonium chloride (BAC, Japanese Pharmacopoeia) was used. ATP extraction reagent was prepared by dissolving this surfactant at 0.25% concentration into 25mM Tricine (pH 7.75).

##### (2) Microorganisms

Four strains, *Escherichia coli* (ATCC 25922), *Staphylococcus aureus* (ATCC 25923), *Pseudomonas aeruginosa* (ATCC 27853) and *Enterococcus faecalis* (ATCC 29212) were used.

##### (3) Preparation of samples

In standard techniques, a sample, undiluted solution, was prepared by culturing the prescribed microorganisms on a normal broth medium (produced by Eiken chemical Co., Ltd.) at 35°C overnight. In the method of the present invention, a sample diluted solution was prepared by diluting an undiluted solution of the culture fluid to 1:100 with sterile water.

##### (4) Luciferase

Surfactant-resistant luciferase of the present invention were HIK and HLK. Control surfactant-resistant luciferase types were known luciferase (North American firefly luciferase, GENJI firefly luciferase, HEIKE firefly luciferase, HEIKE I mutant, and HEIKE L mutant).

##### (5) Luminescence reagent

Luminescence reagent was prepared by adding various luciferase to solution containing 0.15mM luciferin, 6mM EDTA, 15mM magnesium acetate, 0.2mM dithiothreitol, 0.5% BSA and 25mM HEPES (pH 7.75).

[0075] The amount of luciferase to be added was prepared such that the light emission produced when 100  $\mu$ l of  $2 \times 10^{-8}$  M ATP standard solution was added to 100  $\mu$ l of the luminescence reagent would be the same amount of the light emission produced when a luminescence reagent attached to Luciferase LU (Kikkoman Corporation) was used.

#### 2. Method for measuring intracellular ATP

##### [0076]

##### (1) Method of the present invention

ATP extraction reagent 100  $\mu$ l was added to 100  $\mu$ l of a sample. The solution was allowed to stand for 20 seconds at room temperature. Then 100  $\mu$ l of the luminescence reagent was added to this solution. Immediately after addition, the light emission was measured using Lumal LB-9501 produced by Berthold.

##### (2) Standard technique

10 % trichloro acetate solution 100  $\mu$ l was added to 100  $\mu$ l of a sample and the solution was allowed to stand for 1 minute. 25 mM Tricine (pH 7.75) 9.8ml was added to this extract, and then the extract was well stirred. 25 mM Tricine (pH 7.75) and 100  $\mu$ l of a luminescence reagent attached to CheckLite LU (produced by Kikkoman Corporation) were added to 100 l of the sample. Immediately after addition, the light emission was measured using Lumal LB-9501 produced by Berthold.

## EP 1 041 151 A1

## 3. Results

[0077] Tables 3 and 4 show the results. The relative ratio of the light emissions obtained by the use of the luminescence reagents using various luciferase types is also shown in these tables. Here the light emission obtained by the standard technique (TCA extraction method) was defined as 100%.

Table 3

Detection of intracellular ATP				
Measuring method	E.coli ATCC25922		S.aureus ATCC 25923	
	Measured value (RLU)	Relative ratio (%)	Measured value(RLU)	Relative ratio (%)
Standard technique (TCA extraction method)	132794	(100.0)	130220	(100.0)
North American firefly	153	(0.1)	163	(0.1)
GENJI firefly luciferase	463	(0.3)	659	(0.5)
HEIKE firefly luciferase	76082	(57.3)	74019	(56.8)
HEIKE I mutant	47655	(35.9)	50031	(38.4)
HEIKE L mutant	46217	(34.8)	51243	(39.4)
HIK	97073	(73.1)	76533	(58.8)
HLK	87981	(66.3)	72182	(55.4)

Table 4

Detection of intracellular ATP				
Measuring method	P.aeruginosa ATCC 27853		E.faecalis ATCC 29212	
	Measured value(RLU)	Relative ratio (%)	Measured value(RLU)	Relative ratio (%)
Standard technique (TCA extraction method)	168141	(100.0)	12427	(100.0)
North American firefly	553	(0.3)	113	(0.1)
GENJI firefly luciferase	1503	(0.9)	163	(1.3)
HEIKE firefly luciferase	117096	(69.6)	8132	(65.4)
HEIKE I mutant	80455	(47.8)	4586	(36.9)
HEIKE L mutant	81069	(48.2)	4762	(38.3)
HIK	131134	(78.0)	7914	(63.7)
HLK	131815	(78.4)	7998	(64.4)

[0078] No emission was observed for the luminescence reagent containing North American firefly luciferase. GENJI firefly luciferase showed weak emission. This is because the luciferase itself was devitalized by the surfactant. Therefore, it was shown that the surfactant at high concentration such as was used in this examination cannot be used

## EP 1 041 151 A1

as an ATP extraction reagent for the luciferase.

[0079] Unlike North American firefly luciferase and GENJI firefly luciferase, HEIKE firefly luciferase showed emission 60 to 70% of that in TCA extraction method. HEIKE firefly luciferase was shown to possess surfactant-resistance higher than those of North American firefly luciferase and GENJI firefly luciferase.

[0080] Light emissions from HEIKE L mutant, and HEIKE I mutant which is thermostable HEIKE firefly luciferase were each equivalent to around 40% of that in TCA extraction method, and largely lower than that of wild-type HEIKE firefly luciferase.

[0081] Each of the light emission from HIK and HLK, which is surfactant-resistant luciferase of the present invention, respectively was more intense than that from wild-type HEIKE luciferase and thermostable luciferase. Further the light emission in this case was equivalent to 60 to 80% of that in TCA extraction method.

[0082] HIK and HLK are mutants wherein Glu at the 490-position of HEIKE I and HEIKE L mutants are substituted for Lys, respectively. That is, the introduction of said mutation into the amino acid at the 490-position improved resistance to a surfactant. The sensitivity of HIK and HLK is less affected by ATP extraction reagent even at such a high concentration employed in this examination, suggesting the use of HIK and HLK enable highly accurate measurement.

#### Industrial Applicability

[0083] The use of a novel surfactant-resistant luciferase according to the present invention for measuring intracellular ATP allows the detection without a decrease in luciferase activity even in the presence of a surfactant at a high concentration.

[0084] All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety.

#### Sequence Listing Free Text

[0085]

SEQ ID NO:1: A synthetic DNA

SEQ ID NO:2: A synthetic DNA

## EP 1 041 151 A1

## SEQUENCE LISTING

&lt;110&gt; KIKKOMAN CORPORATION

<120> LUCIFERASE AND METHOD FOR ASSAYING INTRACELLULAR ATP  
BY USING THE SAME

&lt;130&gt; AHB/FP5864723

&lt;140&gt; EP 98961523.2

&lt;141&gt; 1998-12-24

&lt;150&gt; PCT/JP98/05864

&lt;151&gt; 1998-12-24

&lt;150&gt; JP 361022/1997

&lt;151&gt; 1997-12-26

&lt;160&gt; 6

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic DNA

&lt;400&gt; 1

tggtgtactt aagaaggaa aat

23

&lt;210&gt; 2

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic DNA

&lt;400&gt; 2

acagctcccg gaagctcacc agc

23

&lt;210&gt; 3

&lt;211&gt; 1644

&lt;212&gt; DNA

&lt;213&gt; Luciola lateralis

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1) .. (1644)

&lt;400&gt; 3

atg gaa aac atg gag aac gat gaa aat att gtg tat ggt cct gaa cca 48

Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro

1

5

10

15

ttt tac cct att gaa gag gga tct gct gga gca caa ttg cgc aag tat 96

## EP 1 041 151 A1

Phe Tyr Pro Ile Glu Gly Ser Ala Gly Ala Gln Leu Arg Lys Tyr  
 20 25 30  
 5 arg gat cga tat gca aaa ctt gga gca att gct ttt act aac gca ctt 144  
 Met Asp Arg Tyr Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu  
 35 40 45  
 10 acc ggt gtc gat tat acg tac gcc gaa tac tta gaa aaa tca tgc tgt 192  
 Thr Gly Val Asp Tyr Thr Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys  
 50 55 60  
 cta gga gag gct tta aag aat tat ggt ttg gtt gtt gat gga aga att 240  
 Leu Gly Glu Ala Leu Lys Asn Tyr Gly Leu Val Val Asp Gly Arg Ile  
 65 70 75 80  
 15 gog tta tgc agt gaa aac tgt gaa gaa ttc ttt att cct gta tta gcc 288  
 Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe Phe Ile Pro Val Leu Ala  
 85 90 95  
 ggt tta ttt ata ggt gtc ggt gtg gct cca act aat gag att tac act 336  
 Gly Leu Phe Ile Gly Val Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr  
 100 105 110  
 cta cgt gaa ttg gtt cac agt tta ggc atc tct aag cca aca att gta 384  
 Leu Arg Glu Leu Val His Ser Leu Gly Ile Ser Lys Pro Thr Ile Val  
 115 120 125  
 25 ttt agt tct aaa aaa gga tta gat aaa gtt ata act gta caa aaa acg 432  
 Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr  
 130 135 140  
 gta act gct att aaa acc att gtt ata ttg gac agc aaa gtg gat tac 480  
 Val Thr Ala Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr  
 145 150 155 160  
 30 aga ggt tat caa tcc atg gac aac ttt att aaa aaa aac act cca caa 528  
 Arg Gly Tyr Gln Ser Met Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln  
 165 170 175  
 ggt ttc aaa gga tca agt ttt aaa act gta gaa gtt aac cgc aaa gaa 576  
 Gly Phe Lys Gly Ser Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu  
 180 185 190  
 caa gtt gct ctt ata atg aac tct tog ggt tca acc ggt ttg cca aaa 624  
 Gln Val Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys  
 195 200 205  
 ggt gtg caa ctt act cat gaa aat ttg gtc act aga ttt tct cac gct 672  
 Gly Val Gln Leu Thr His Glu Asn Leu Val Thr Arg Phe Ser His Ala  
 210 215 220  
 45 aga gat cca att tat gga aac caa gtt tca cca ggc acg gct att tta 720  
 Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Ile Leu  
 225 230 235 240  
 act gta gta cca ttc cat cat ggt ttt ggt atg ttt act act tta ggc 768  
 Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly  
 245 250 255  
 50 tat cta act tgt ggt ttt cgt att gtc atg tta acg aaa ttt gac gaa 816  
 Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe Asp Glu

## EP 1 041 151 A1

	260	265	270	
5	gag act ttt tta aaa aca ctg caa gat tac aaa tgt tca agc gtt att Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile 275 280 285	864		
10	ctt gta ccg act ttg ttt gca att ctt aat aga agt gaa tta ctc gat Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp 290 295 300	912		
15	aaa tat gat tta tca aat tta gtt gaa att gca tct ggc gga gca cct Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro 305 310 315 320	960		
20	tta tct aaa gaa att ggt gaa gct gtt gct aga cgt ttt aat tta ccg 1008 Leu Ser Lys Glu Ile Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro 325 330 335			
25	ggc gct cgt caa ggc tac ggt tca aca gaa aca acc tct gca att att 1056 Gly Val Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile 340 345 350			
30	atc aca ccg gaa ggc gat gat aaa cca ggt gct tct ggc aaa gtt gtg 1104 Ile Thr Pro Glu Gly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val 355 360 365			
35	cca tta ttt aaa gca aaa gtt atc gat ctt gat act aaa aaa act ttg 1152 Pro Leu Phe Lys Ala Lys Val Ile Asp Leu Asp Thr Lys Lys Thr Leu 370 375 380			
40	ggc ccg aac aga cgt gga gaa gtt tgt gta aag ggt cct arg ctt atg 1200 Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met 385 390 395 400			
45	aaa ggt tat gta gat aat cca gaa gca aca aga gaa atc ata gat gaa 1248 Lys Gly Tyr Val Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile Asp Glu 405 410 415			
50	gaa ggt tgg ttg cac aca gga gat att ggg tat tac gat gaa gaa aaa 1296 Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys 420 425 430			
55	cat ttc ttt atc gtg gat cgt ttg aag tct tta atc aaa tac aaa gga 1344 His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly 435 440 445			
	tat caa gta cca cct gct gaa tta gaa tct gtt ctt ttg caa cat cca 1392 Tyr Gln Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro 450 455 460			
	aat att ttt gat gcc ggc gtt gct ggc gtt cca gat cct ata gct ggt 1440			

## EP 1 041 151 A1

Asn Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly  
465 470 475 480

gag ctt ccg gga gct gct gtt gta ctt aag aaa gga aaa tct atg act  
1488

Glu Leu Pro Gly Ala Val Val Val Leu Lys Lys Gly Lys Ser Met Thr  
485 490 495

gaa aaa gaa gta atg gat tac gtt gct agt caa gtt tca aat gca aaa  
1536

Glu Lys Glu Val Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys  
500 505 510

cgt ttg cgt ggt ggt gtc cgt ttt gtg gac gaa gta cct aaa ggt ctc  
1584

Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys Gly Leu  
515 520 525

act ygt aaa att gac ggt aaa gca att aga gaa ata ctg aag aaa cca  
1632

Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile Leu Lys Lys Pro  
530 535 540

gtt gct aag atg

1644

Val Ala Lys Met

545

<210> 4

<211> 548

<212> PRT

<213> *Luciola lateralis*

<400> 4

Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro  
1 5 10 15

Phe Tyr Pro Ile Glu Glu Gly Ser Ala Gly Ala Gln Leu Arg Lys Tyr  
20 25 30

Met Asp Arg Tyr Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu  
35 40 45

Thr Gly Val Asp Tyr Thr Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys  
50 55 60

Leu Gly Glu Ala Leu Lys Asn Tyr Gly Leu Val Val Asp Gly Arg Ile  
65 70 75 80

Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe Phe Ile Pro Val Leu Ala  
85 90 95

Gly Leu Phe Ile Gly Val Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr  
100 105 110

Leu Arg Glu Leu Val His Ser Leu Gly Ile Ser Lys Pro Thr Ile Val  
115 120 125

Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr  
130 135 140



## EP 1 041 151 A1

Val Thr Ala Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr  
 145 150 155 160  
 5 Arg Gly Tyr Gln Ser Met Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln  
 165 170 175  
 Gly Phe Lys Gly Ser Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu  
 180 185 190  
 10 Gln Val Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys  
 195 200 205  
 Gly Val Gln Leu Thr His Glu Asn Leu Val Thr Arg Phe Ser His Ala  
 210 215 220  
 15 Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Ile Leu  
 225 230 235 240  
 Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly  
 245 250 255  
 20 Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe Asp Glu  
 260 265 270  
 Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile  
 275 280 285  
 25 Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp  
 290 295 300  
 Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro  
 305 310 315 320  
 30 Leu Ser Lys Glu Ile Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro  
 325 330 335  
 Gly Val Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile  
 340 345 350  
 35 Ile Thr Pro Glu Gly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val  
 355 360 365  
 Pro Leu Phe Lys Ala Lys Val Ile Asp Leu Asp Thr Lys Lys Thr Leu  
 370 375 380  
 40 Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met  
 385 390 395 400  
 Lys Gly Tyr Val Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile Asp Glu  
 405 410 415  
 45 Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys  
 420 425 430  
 His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly  
 435 440 445  
 50 Tyr Gln Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro  
 450 455 460  
 Asn Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly

55

## EP 1 041 151 A1

465 470 475 480

Glu Leu Pro Gly Ala Val Val Val Leu Lys Lys Gly Lys Ser Met Thr  
485 490 495

Glu Lys Glu Val Met Asp Tyr Val Ala Ser Glu Val Ser Asn Ala Lys  
500 505 510

Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys Gly Leu  
515 520 525

Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile Leu Lys Lys Pro  
530 535 540

Val Ala Lys Met  
545

<210> 5  
<211> 1644  
<212> DNA  
<213> *Luciola lateralis*

<220>  
<221> CD6  
<222> (1)..(1644)

<400> 5

atg gaa aac atg gag aac gat gaa aat att gtg tat ggt cct gaa cca 48  
Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro  
1 5 10 15

ttt tac cct att gaa gag gga tct gct gga gca caa ttg cgc aag tat 96  
Phe Tyr Pro Ile Glu Glu Gly Ser Ala Gly Ala Glu Leu Arg Lys Tyr  
20 25 30

atg gat cga tat gca aac ctt gga gca att gct ttt act aac gca ctt 144  
Met Asp Arg Tyr Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu  
35 40 45

acc ggt gcc gat tat acg tac gcc gaa tac tta gaa aac tca tgc tgc 192  
Thr Gly Val Asp Tyr Thr Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys  
50 55 60

cta gga gag gct tta aag aat tat ggt ttg gtt gtt gat gga aga att 240  
Leu Gly Glu Ala Leu Lys Asn Tyr Gly Leu Val Val Asp Gly Arg Ile  
65 70 75 80

gcg tta tgc agt gaa aac tgt gaa gaa ttc ttt att cct gta tta gcc 288  
Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe Phe Ile Pro Val Leu Ala  
85 90 95

ggc tta ttt ata ggt gtc ggt gtg gct cca act aat gag att tac act 336  
Gly Leu Phe Ile Gly Val Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr  
100 105 110

cta cgt gaa ttg gtt cac agt tta ggc atc tct aag cca aca att gta 384  
Leu Arg Glu Leu Val His Ser Leu Gly Ile Ser Lys Pro Thr Ile Val  
115 120 125

ttt agt tct aaa aaa gga tta gat aaa gtt ata act gta caa aaa acg 432

## EP 1 041 151 A1

Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr  
 130 135 140  
 5 gta act gct att aaa acc att gtt ata ttg gac agc aaa gtg gat tat 480  
 Val Thr Ala Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr  
 145 150 155 160  
 10 aga ggt tat caa tcc atg gac aac ttt att aaa aaa aac act cca caa 528  
 Arg Gly Tyr Gln Ser Met Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln  
 165 170 175  
 ggt ttc aaa gga tca agt ttt aaa act gta gaa gtt aac cgc aaa gaa 576  
 Gly Phe Lys Gly Ser Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu  
 180 185 190  
 15 caa gtt gct ctt ata atg aac tct tgg ggt tca acc ggt ttg cca aaa 624  
 Gln Val Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys  
 195 200 205  
 20 ggt gtg caa ctt act cat gaa aat atc gtc act aga ttt tct cac gct 672  
 Gly Val Gln Leu Thr His Glu Asn Ile Val Thr Arg Phe Ser His Ala  
 210 215 220  
 aga gat cca att tat gga aac caa gtt tca cca ggt acg gct att tta 720  
 Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Ile Leu  
 225 230 235 240  
 25 act gta gta cca ttc cat cat ggt ttt ggt atg ttt act act tta ggc 768  
 Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly  
 245 250 255  
 30 tat cta act tgt ggt ttt cgt att gtc atg tta acg aaa ttt gac gaa 816  
 Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe Asp Glu  
 260 265 270  
 gag act ttt tta aaa aca ctg caa gat tac aaa tgt tca agc gtt att 864  
 Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile  
 275 280 285  
 35 ctt gta ccg act ttg ttt gca att ctt aat aga agt gaa tta ctc gat 912  
 Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp  
 290 295 300  
 40 aaa tat gat tta tca aat tta gtt gaa att gca tct ggc gga gca cct 960  
 Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro  
 305 310 315 320  
 tta tct aaa gaa att ggt gaa got gtt gct aga cgt ttt aat tta ccg  
 1008  
 Leu Ser Lys Glu Ile Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro  
 325 330 335  
 45 ggt gtt cgt caa ggc tat ggt tta aca gaa aca acc tct gca att att  
 1056  
 Gly Val Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile  
 340 345 350  
 50 atc aca ccg gaa ggc gat gat aaa cca ggt gct tct ggc aaa gtt gtg  
 1104  
 Ile Thr Pro Glu Gly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val  
 355 360 365

55

## EP 1 041 151 A1

cca tta ttt aaa gca aaa gtt atc gat ctt gat act aaa aaa act ttg  
1152

Pro Leu Phe Lys Ala Lys Val Ile Asp Leu Asp Thr Lys Lys Thr Leu  
370 375 380

ggc ccg aac aga cgt gga gaa gtt tgt gta aag ggt cct atg ctt atg  
1200

Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met  
385 390 395 400

aaa ggt tat gta gat aat cca gaa gca nca aga gaa atc ata gat gaa  
1248

Lys Gly Tyr Val Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile Asp Glu  
405 410 415

gaa ggt tgg ttg cac aca gga gat att ggg tat tac gat gaa gaa aaa  
1296

Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys  
420 425 430

cat ttc ttt atc gtg gat cgt ttg aag tct tta atc aaa tac aaa gga  
1344

His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly  
435 440 445

tat caa gta cca cct gct gaa tta gaa tct gtt ctt ttg caa cat cca  
1392

Tyr Gln Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro  
450 455 460

aat att ttt gat gcc ggc gtt gct ggc gtt cca gat cct ata gct ggt  
1440

Asn Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly  
465 470 475 480

gag ctt ccg gga gct gtt gtt gta ctt aag aaa gga aaa tct atg act  
1488

Glu Leu Pro Gly Ala Val Val Val Leu Lys Lys Gly Lys Ser Met Thr  
485 490 495

gaa aas gaa gta atg gat tac gtt gct agt caa gtt tca aat gca aaa  
1536

Glu Lys Glu Val Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys  
500 505 510

cgt ttg cgt ggt ggt gtc cgt ttt gtg gac gaa gta cct aaa ggt ctc  
1584

Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys Gly Leu  
515 520 525

act ggt aaa att gac ggt aaa gca att age gaa ata ctg aag aaa cca  
1632

Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile Leu Lys Lys Pro  
530 535 540

gtt gct aag atg  
1644

Val Ala Lys Met  
545

## EP 1 041 151 A1

&lt;210&gt; 6

&lt;211&gt; 548

&lt;212&gt; PRT

<213> *Luciola lateralis*

&lt;400&gt; 6

Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro  
 1 5 10 15

Phe Tyr Pro Ile Glu Glu Gly Ser Ala Gly Ala Gln Leu Arg Lys Tyr  
 20 25 30

Met Asp Arg Tyr Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu  
 35 40 45

Thr Gly Val Asp Tyr Thr Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys  
 50 55 60

Leu Gly Glu Ala Leu Lys Asn Tyr Gly Leu Val Val Asp Gly Arg Ile  
 65 70 75 80

Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe Phe Ile Pro Val Leu Ala  
 85 90 95

Gly Leu Phe Ile Gly Val Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr  
 100 105 110

Leu Arg Glu Leu Val His Ser Leu Gly Ile Ser Lys Pro Thr Ile Val  
 115 120 125

Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr  
 130 135 140

Val Thr Ala Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr  
 145 150 155 160

Arg Gly Tyr Gln Ser Met Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln  
 165 170 175

Gly Phe Lys Gly Ser Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu  
 180 185 190

Gln Val Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys  
 195 200 205

Gly Val Gln Leu Thr His Glu Asn Ile Val Thr Arg Phe Ser His Ala  
 210 215 220

Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Ile Leu  
 225 230 235 240

Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly  
 245 250 255

Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe Asp Glu  
 260 265 270

Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile  
 275 280 285

## EP 1 041 151 A1

Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp  
 290 295 300  
 Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro  
 305 310 315 320  
 Leu Ser Lys Glu Ile Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro  
 325 330 335  
 Gly Val Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile  
 340 345 350  
 Ile Thr Pro Glu Gly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val  
 355 360 365  
 Pro Leu Phe Lys Ala Lys Val Ile Asp Leu Asp Thr Lys Lys Thr Leu  
 370 375 380  
 Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met  
 385 390 395 400  
 Lys Gly Tyr Val Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile Asp Glu  
 405 410 415  
 Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys  
 420 425 430  
 His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly  
 435 440 445  
 Tyr Gln Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro  
 450 455 460  
 Asn Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly  
 465 470 475 480  
 Glu Leu Pro Gly Ala Val Val Val Leu Lys Lys Gly Lys Ser Met Thr  
 485 490 495  
 Glu Lys Glu Val Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys  
 500 505 510  
 Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys Gly Leu  
 515 520 525  
 Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile Leu Lys Lys Pro  
 530 535 540  
 Val Ala Lys Met  
 545

## 55 Claims


1. Alluciferase having resistance to a surfactant.

## EP 1 041 151 A1

2. The luciferase of claim 1 wherein an amino acid corresponding to that at the 490-position of luciferase from Genji or Heike firefly is substituted by an amino acid other than glutamic acid in the amino acid sequence of firefly luciferase.
- 5 3. The luciferase of claim 2 wherein the amino acid other than glutamic acid is lysine.
4. The luciferase of claim 1 wherein it is:
- 10 (a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:4; or  
(b) a polypeptide comprising additions, deletions or substitutions of one or more amino acids in the amino acid sequence of the polypeptide defined in (a) and having luciferase activity resistant to a surfactant.
5. The luciferase of claim 1 wherein it is:
- 15 (a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:6; or  
(b) a polypeptide comprising additions, deletions, or substitutions of one or more amino acids in the polypeptide defined in (a) and having luciferase activity resistant to a surfactant.
6. A luciferase gene encoding the luciferase of any one of claim 1 to 5.
- 20 7. A recombinant vector comprising the luciferase gene of claim 6.
8. A transformant comprising the recombinant vector of claim 7.
- 25 9. A method for producing a luciferase wherein the method comprising culturing the transformant of claim 8 in a medium and recovering the luciferase from the resulting culture.
10. A method for measuring intracellular ATP characterized in that a luciferase having resistance to a surfactant is used as a luciferase for use in the method comprising a first step wherein ATP is extracted in the presence of the surfactant from cells in a sample, a second step wherein a luminescence reagent containing luciferase is added to the extracted ATP solution to cause emission of light, and a third step wherein the amount of light emission is measured.
- 30 11. The method for measuring intracellular ATP of claim 10 wherein the luciferase having resistance to a surfactant is a luciferase of any one of claim 1 to 5.
- 35 12. The method for measuring intracellular ATP of claim 10 or 11 wherein the light emission is caused by addition of a luminescence reagent in the presence of a surfactant of 0.01% or more.
- 40 13. The method for measuring intracellular ATP of claim 10, 11 or 12 wherein the surfactant is any of a cationic surfactant, an anionic surfactant, a nonionic surfactant, and an ampholytic surfactant.
- 45
- 50
- 55

EP 1 041 151 A1

Figure 1




LIL; *Luciola lateralis* luciferase cDNA, Ap;  $\beta$ -lactamase gene, LacP;  $\beta$ -galactosidase promoter, RI; *EcoRI*, RV; *EcoRV*, Nr; *NarI*




EP 1 041 151 A1

Figure 2




EP 1 041 151 A1

Figure 3



EP 1 041 151 A1

Figure 4



EP 1 041 151 A1

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/05864

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>1</sup> C12N15/53, C12N9/02, C12N15/63, C12N1/21, C12Q1/26		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>1</sup> C12N15/53, C12N9/02, C12N15/63, C12N1/21, C12Q1/26		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) BIOSIS (DIALOG), JICST File (JOIS), GeneBank/EMBL/DBJ (GENETYX)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP, 7-203995, A (Toa Electronics Ltd.), 8 August, 1995 (08. 08. 95), Full text ; Fig. 1 (Family: none)	1, 6-13
Y	JP, 6-504200, A (Amarsham International PLC), 19 May, 1994 (19. 05. 94), Full text ; Figs. 1 to 20 £ WO, 92/12253, A1 £ EP, 566625, A1 £ US, 5558986, A	1, 6-13
Y	W.J. Simpson et al., "The Effect of Detergents on Firefly Luciferase Reactions", Journal of Bioluminescence and Chemiluminescence, Vol. 6(2), 1991, p.97-106	1, 6-13
Y	JP, 5-244942, A (Rikkoman Corp.), 24 September, 1993 (24. 09. 93), Full text ; Figs. 1, 2 £ EP, 524440, A1 £ US, 5229285, A	1, 6-13
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to underline the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document members of the same patent family		
Date of the actual completion of the international search 17 March, 1999 (17. 03. 99)		Date of mailing of the international search report 30 March, 1999 (30. 03. 99)
Name and mailing address of the ISA Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

EP 1 041 151 A1

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/05864

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 2-171189, A (Kikkoman Corp.), 2 July, 1990 (02. 07. 90), Full text ; Figs. 1 to 8 & EP, 353464, B1	1-9
A	Hiroki Tatsumi et al., "Molecular Cloning and Expression in Escherichia Coli of a cDNA Clone Encoding Luciferase of a Firefly, <i>Luciola lateralis</i> ", <i>Biochimica et Biophysica Acta</i> , Vol. 1131, 1992, p.161-165	1-9
A	Tsutomu Masuda et al., "Cloning and Sequence Analysis of cDNA for Luciferase of a Japanese Firefly, <i>Luciola cruciata</i> ", <i>Gene</i> , Vol. 77, 1988, p.265-270	1-9

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**